Please assess the completion status of the following clinical trial:

Trial Title: A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of the Anti-Orthopoxvirus Compound Tecovirimat

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 to 80 years old, inclusive~* Available for clinical follow-up for the duration of the study~* Able and willing to give informed consent~* In good general health without clinically significant medical history; not have been hospitalized for a chronic medical condition for the last 2 years~* Able to comply with dietary requirements throughout the study drug dosing period~* Adequate venous access for those individuals participating in PK testing~* PE and laboratory results without clinically significant findings within the 14 days before receipt of study drug~* Agree not to drink alcohol from the beginning of the Screening Period through the completion of the Day 28 Follow up Visit~* Agree not to use any nicotine products, including electronic vapor cigarettes, nicotine patches or nicotine gum for at least 30 days before the Day 1 Visit and through completion of the Day 15 Dosing complete Visit~* Agree not to consume caffeine during all study visits, including overnight stays if participating in PK subset~* Agree not to receive any immunizations/vaccinations~* Agree not to take herbal products~* Able and willing to refrain from taking any prescriptions and nonprescription medications with exceptions~* For women of childbearing potential, negative serum and urine pregnancy testing~* If male, agree not to donate sperm~* Meet 1 of the following criteria: The subject or their partner has undergone surgical sterilization; the subject is postmenopausal; the subject agrees to be abstinent; the subject agrees to consistently use a method of approved birth control.~Exclusion Criteria:~* Pregnant or breast-feeding or planning pregnancy~* Have a history of any clinically significant conditions~* Have any limitation of activity related to cardiac disease~* Have a bleeding disorder diagnosed by a doctor, or a history of significant bruising or bleeding with intramuscular injections or blood draws~* Currently using certain medications~* Have a malignancy that is active or a treated malignancy for which there is no reasonable assurance of sustained cure, or malignancy that is likely to recur during the study~* Have a history of seizure~* Have a clinically significant blood dyscrasia~* Have a history of drug allergy that contraindicates participation in the trial~* Have a medical, psychiatric, or social condition or any occupational reason, or other responsibility that in the judgment of the investigator would render the subject unable to comply with the protocol~* Have an inability to swallow medication~* Have a clinically significant abnormal ECG~* Have participated in a clinical trials within 30 days of study entry or planning to participate in any experimental treatment study during the study period~* Have a history or current drug or alcohol abuse~* Have received immunizations/vaccines~* Have a current clinically significant acute bacterial, fungal, or mycobacterial infection requiring administration of systemic antibiotics~* Have known chronic bacterial, mycobacterial, fungal, parasitic, or protozoal infection with the exception of clinically significant dermal infections~* Have known hepatitis B or C infection, or positive test result~* Have known HIV infection or AIDS or a positive test for HIV~* Have a current clinically significant viral infection~* Have known clinically significant chronic viral infection~* have received treatment with greater than 20 mg prednisone or equivalent dose or any immunosuppressant or immunomodulary medication~* Have abnormal laboratory testing during screening~* Have a greater than or equal than 20% risk of suffering a major cardiovascular event~* Have been previously enrolled in this or any clinical trial involving tecovirimat

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- Active (Type: ACTIVE_COMPARATOR): 600 mg tecovirimat capsules BID to assess safety and tolerability and pharmacokinetics of the anit-orthopoxvirus compound Tecovirimat when administered orally in healthy subjects
- Placebo (Type: PLACEBO_COMPARATOR): matching placebo capsules BID to assess safety and tolerability and pharmacokinetics of the anit-orthopoxvirus compound Tecovirimat when administered orally in healthy subjects

Based on this trial design, predict the completion outcome and termination type (if applicable).